reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

Kiora Pharmaceuticals Inc

KPRX · Nasdaq

No reporting failures in the last 12 months

It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.

$10Mpublic float
2023-03-30most recent failure
2022-05-23declared past accounts unreliable

Score over time

0123202220232024202520262022-04-01 · score 12022-03-31 filed late (10-K) · material weakness2022-07-01 · score 32022-05-23 accounts unreliable2022-05-17 filed late (10-Q) · accounts not ready2022-03-31 filed late (10-K) · material weakness2022-10-01 · score 32022-05-23 accounts unreliable2022-05-17 filed late (10-Q) · accounts not ready2022-03-31 filed late (10-K) · material weakness2023-01-01 · score 32022-05-23 accounts unreliable2022-05-17 filed late (10-Q) · accounts not ready2022-03-31 filed late (10-K) · material weakness2023-04-01 · score 32023-03-30 auditor change2022-05-23 accounts unreliable2022-05-17 filed late (10-Q) · accounts not ready2023-07-01 · score 12023-03-30 auditor change2023-10-01 · score 12023-03-30 auditor change2024-01-01 · score 12023-03-30 auditor change

Hover or tap a dot to see the filings behind that score.

Why they said they were late

Kiora Pharmaceuticals, Inc. (the “Company”) is unable to file its Form 10-Q for the quarter ended March 31, 2022 (the “Form 10-Q”) in a timely manner without unreasonable effort and expense due to unanticipated delays experienced by the Company in completing its financial statements and other disclosures in the Form 10-Q, primarily due to an assessment of contingent consideration liability. As a result, the Company is still in the process of compiling required information to complete the Form 10-Q and requires additional time to complete its review of the financial statements for the quarter ended March 31, 2022 to be incorporated in the Form 10-Q. The Company presently anticipates that it will file the Form 10-Q before the fifth calendar day following the prescribed due date

NT 10-Q, filed 2022-05-17 · accounts not ready

What it filed

2023-03-30auditor changed or resigned SEC →

2022-05-23accounts declared unreliable SEC →

2022-05-17filed late (10-Q)accounts not ready SEC →

Kiora Pharmaceuticals, Inc. (the “Company”) is unable to file its Form 10-Q for the quarter ended March 31, 2022 (the “Form 10-Q”) in a timely manner without unreasonable effort and expense due to unanticipated delays experienced by the Company in completing its financial statements and other disclosures in the Form 10-Q, primarily due to an assessment of contingent consideration liability. As a result, the Company is still in the process of compiling required information to complete the Form 10-Q and requires additional time to complete its review of the financial statements for the quarter ended March 31, 2022 to be incorporated in the Form 10-Q. The Company presently anticipates that it will file the Form 10-Q before the fifth calendar day following the prescribed due date

2022-03-31filed late (10-K)material weakness SEC →

Kiora Pharmaceuticals, Inc. (the “Company”) is unable to file its Form 10-K for the year ended December 31, 2021 (the “Form 10-K”) in a timely manner without unreasonable effort and expense due to unanticipated delays experienced by the Company in completing its financial statements and other disclosures in the Form 10-K, primarily due to an ongoing assessment of potential impairment of the Company’s goodwill and/or intangible assets. As a result, the Company is still in the process of compiling required information to complete the Form 10-K and requires additional time to complete its review of the financial statements for the year ended December 31, 2021 to be incorporated in the Form 10-K and to complete its assessment of the Company’s internal control over financial reporting. The Company presently anticipates that it will file the Form 10-K before the fifteenth calendar day following the prescribed due date

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com